← Leaderboards
Christopher John Burns
Protez Pharmaceuticals, Inc.
$15,283,294
Attributed
$20,423,912
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$20,423,912 · 8
By mechanism
R01$10,186,851 · 2
R44$6,000,000 · 2
U01$2,437,061 · 1
R43$1,800,000 · 3
Top collaborators
- Luigi Xerri11 shared
Others in their field
Top investigators on “Enterobacteriaceae”
- Luigi Xerri · Venatorx Pharmaceuticals, Inc.$11,437,618
- Bernhard O Palsson · University Of California San Diego$11,426,034
- Derrick E Fouts · Institute For Genomic Research$9,984,682
- Ryan Balfour Sartor · Univ Of North Carolina Chapel Hill$9,968,217
- Andreas J Baumler · Texas A&M University Health Science Ctr$9,514,828
- Ashlee Miriam Earl · University Of California-Irvine$9,311,791
Research focus
EnterobacteriaceaePre-ClinicalInhibitor/AntagonistToxicologyScale UpGenerationsIn VivoResistanceInfectionPathogenHospitalsSeriesPharmacologyMonobactamsLactamaseEnzymesBeta-LactamaseLeadLactamsCephalosporinsProgramsBackSafetyAntibiotics
Grant awards (22)
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$1,000,000
R44 · FY2020 · AI · contact PI
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$1,000,000
R44 · FY2019 · AI · contact PI
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$1,000,000
R44 · FY2018 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,446,843
R01 · FY2017 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,446,843
R01 · FY2016 · AI · contact PI
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$300,000
R43 · FY2016 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,448,775
R01 · FY2015 · AI · contact PI
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase$1,000,000
R44 · FY2015 · AI · contact PI
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$300,000
R43 · FY2015 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,738,775
R01 · FY2014 · AI · contact PI
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase$1,000,000
R44 · FY2014 · AI · contact PI
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase$1,000,000
R44 · FY2013 · AI · contact PI
Novel Compounds Targeting Bacterial PBPs$300,000
R43 · FY2013 · AI · contact PI
Development of New Beta-Lactamase Inhibitors for Resistant Category B Food/Water-$1,358,378
R01 · FY2012 · AI · contact PI
Novel Compounds Targeting Bacterial PBPs$300,000
R43 · FY2012 · AI · contact PI
Preserving beta-lactam utility against pathogens producing all classes of beta-la$300,000
R43 · FY2012 · AI · contact PI
Development of New Beta-Lactamase Inhibitors for Resistant Category B Food/Water-$1,371,474
R01 · FY2011 · AI · contact PI
Development of New Beta-Lactamase Inhibitors for Resistant Category B Food/Water-$426,165
R01 · FY2011 · AI · contact PI
Preserving beta-lactam utility against pathogens producing all classes of beta-la$300,000
R43 · FY2011 · AI · contact PI
Development of New Beta-Lactamase Inhibitors for Resistant Category B Food/Water-$949,598
R01 · FY2010 · AI · contact PI
PTE-based drug for antibiotic-resistant anthrax$1,156,790
U01 · FY2005 · AI
PTE-based drug for antibiotic-resistant anthrax$1,280,271
U01 · FY2004 · AI